Capital and Market Dual Endorsement: TingSheng Medical Secures Nearly RMB 100 Million in Series B+ Financing and Receives Fourth ICE Catheter Registration Certificate

Recently, TINGSN has once again attracted attention in the medical device field, with a series of significant positive developments — securing nearly 100 million yuan in B+ round financing, and obtaining official approval from the National Medical Products Administration on June 20, 2025, for its self-developed TINGSN Sonic Eyes 10 Eco intracardiac echocardiography catheter (registration certificate number: NMPA Approval 20253061164). These advancements highlight TINGSN's strong capabilities in technological innovation and market expansion, while also bringing new hope to the global diagnosis and treatment of heart diseases.

TINGSN Sonic Eyes 10 Eco Approved, Accelerating Global Expansion

On June 20, 2025, TINGSN's newly approved Sonic Eyes 10 Eco intracardiac echocardiography catheter (registration certificate number: National Medical Device Approval 20253061164) officially received approval from the National Medical Products Administration. As a key overseas export model developed by TINGSN, it represents the strong capabilities of "Made in China" and will provide a new solution for the diagnosis and treatment of heart diseases globally.

At present, there is an urgent demand among medical institutions for a cost-effective and stable intracardiac echocardiography solution, and Sonic Eyes 10 Eco was developed to meet this need.

As early as November 2023, TINGSN launched the first domestically approved 2D ICE product in China ——"Disposable Intracardiac Echocardiography Diagnostic Catheter" (registration certificate No. 20233061761), also known as TINGSN Sonic Eyes 10. This product has been successfully applied in various types of procedures such as radiofrequency ablation, cryoablation, and left atrial appendage closure at dozens of well-known hospitals across China, earning recognition from clinical experts for its excellent quality. The recent approval of Sonic Eyes 10 Eco marks another significant achievement for TINGSN in expanding its product portfolio. Currently, TINGSN has already initiated the overseas registration and certification process for 10 Eco and plans to achieve market entry in foreign markets in the near future, allowing high-end medical devices created in China to benefit more patients worldwide and promoting Chinese high-end medical equipment on the international stage.

Nearly 100 Million B+ Round Financing to Accelerate 4D ICE R&D Progress

TINGSN's B+ round of financing was led by EF Capital, with existing shareholders Qiming Venture Partners and Huangpu Pharmaceutical Fund following up. Star Bridge Capital served as the exclusive financial advisor. The funds raised in this round will be mainly invested in the subsequent research and development and clinical work of the 4D intracardiac echocardiography (4D ICE) product, laying a solid foundation for the product's process mass production.

At present, there are only three companies globally that have truly completed the ASIC-integrated 4D ICE R&D and entered the clinical trial stage: Philips, Johnson & Johnson, and TINGSN. TINGSN is also the only company in China to achieve this milestone. Developing a 4D ICE product requires overcoming a series of highly challenging technical difficulties, such as ASIC chip R&D, ASIC design and ultrasound transducer design, and qualified chip tape-out. Completing a qualified 4D ICE ASIC delivery involves at least three or more tape-outs, with each ASIC design and tape-out costing nearly 10 million yuan. Completing the ASIC tape-out is just the beginning; establishing a high-end transducer manufacturing system is the key to achieving product commercialization.

Only Four Factories Worldwide Possess Relevant Technical Capabilities, Three of Which Are Overseas, and TINGSN Is the Only Company in China Capable of Independently Achieving Mass Production of Intracardiac Ultrasound Transducers. Moreover, Achieving High-Quality 4D ICE Imaging Also Relies on the Deep Synergistic Development of Ultrasound Hosts. In China, 4D Cardiac Ultrasound Hosts with ASIC Chip Adaptation Capability Are Extremely Rare, with Only 1-2 Companies Meeting the Technical Requirements. TINGSN Has Completed the Layout and Accumulation in These Key Technical Areas, Demonstrating a Significant Leading Advantage.On April 29 this year, TINGSN successfully completed the first 4D ICE human clinical study in China., marking a significant leap for Chinese companies in the field of cardiovascular interventional imaging from "catching up" to "running alongside". It also validates the maturity of its full-chain independent innovation system from the first domestically produced 2D ICE catheter to 4D ICE. This B+ round of financing will further strengthen its advantages in 4D ICE research and development as well as clinical investment, promoting the early market launch of the product.

From completing nearly 100 million yuan in B+ round financing to the successful approval of TINGSN Sonic Eyes 10 Eco, TINGSN has been steadily advancing on the path of technological innovation and product implementation. In the future, with the continuous progress in the development of 4D ICE products and the gradual rollout of Sonic Eyes 10 Eco in global markets, TINGSN is expected to further reshape the market landscape of cardiac disease diagnosis and treatment devices, offering more high-quality and efficient diagnostic and therapeutic options for patients worldwide, and continuously leading China's medical device industry to new heights.